Biotech Industry Veteran K. Peter Hirth Joins Alios BioPharma Board of Directors

SOUTH SAN FRANCISCO, CA--(Marketwire - August 13, 2009) - Alios BioPharma, Inc. has appointed
Plexxikon Founder and Chief Executive Officer K. Peter Hirth, Ph.D., to its
Board of Directors.

"With the recent close of its $32 million Series A financing, Alios
BioPharma is poised to leverage the company's complementary group of
platform technologies to generate multiple distinct therapeutic products,"
said K. Peter Hirth, Ph.D. "Dr. Blatt and his team are currently
developing the Alios portfolio of novel therapeutic agents to treat serious
viral infections such as chronic hepatitis B and C, and respiratory
viruses."

"Peter Hirth has a unique combination of biotechnology entrepreneurial
leadership and business development as well as pharmaceutical discovery and
development experience," commented Lawrence M. Blatt, Ph.D., Founder and
Chief Executive Officer of Alios BioPharma, Inc. "We are fortunate to have
Dr. Hirth contribute his significant small molecule drug development
expertise and his impressive biotech/pharma partnering experience to
Alios."

Dr. Hirth co-founded Plexxikon, a leader in the discovery and development
of novel, small-molecule pharmaceuticals, and has served as its CEO since
its inception in 2000. He has more than 25 years of biotechnology and
pharmaceutical discovery and development experience. Previously, as
president of Sugen, Inc. (until the sale of the company to Pharmacia
Corporation in 1999), he helped build the company from its inception and
advanced several kinase inhibitors through clinical trials for the
treatment of oncology. This includes the drug Sutent®, now owned by
Pfizer through its acquisition of Pharmacia.

Previously, Dr. Hirth was a vice president in research with Boehringer
Mannheim where, among other responsibilities, he successfully led the
company's erythropoietin program. Earlier in his academic career Dr. Hirth
was a research scientist with the Max Planck Institute, following the
completion of his post doctoral work at the University of California, San
Diego. Dr. Hirth received his Ph.D. in molecular genetics from Heidelberg
University, Germany.

About Alios BioPharma

Alios BioPharma, Inc., an emerging biotechnology company headquartered in
South San Francisco, California, is developing novel medicines to treat
viral diseases by activating pathways in the innate immune system. Alios is
pursuing the development of small-molecule and protein therapeutics, each
addressing major commercial market opportunities.